Open AccessEmerging Cellular Therapies for Cancer
Author(s) -
Sònia Guedan,
Marco Ruella,
Carl H. June
Publication year - 2019
Publication title -
annual review of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 18.301
H-Index - 301
eISSN - 1545-3278
pISSN - 0732-0582
DOI - 10.1146/annurev-immunol-042718-041407
Subject(s) - chimeric antigen receptor , biology , immune system , autoimmunity , immunotherapy , genetically engineered , cancer , lymphoma , cancer immunotherapy , synthetic biology , t cell receptor , immunology , computational biology , t cell , genetics , gene
Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently approved by the US Food and Drug Administration and are poised to enter the practice of medicine for leukemia and lymphoma, demonstrating that engineered immune cells can serve as a powerful new class of cancer therapeutics. The emergence of synthetic biology approaches for cellular engineering provides a broadly expanded set of tools for programming immune cells for enhanced function. Advances in T cell engineering, genetic editing, the selection of optimal lymphocytes, and cell manufacturing have the potential to broaden T cell-based therapies and foster new applications beyond oncology, in infectious diseases, organ transplantation, and autoimmunity.